These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37940480)

  • 1. High-grade B-cell lymphoma with MYC and BCL2 rearrangements presenting as a cervical mass.
    Lin C; Kuma L; Shen L
    Pathology; 2024 Jun; 56(4):588-590. PubMed ID: 37940480
    [No Abstract]   [Full Text] [Related]  

  • 2. Cutaneous involvement of high-grade B-cell lymphoma with MYC and BCL6 rearrangements: A case report.
    Maejima E; Oishi N; Ogawa Y; Okamoto T; Mitsui H; Shimada S; Kawamura T
    J Dermatol; 2023 Aug; 50(8):e243-e244. PubMed ID: 36890662
    [No Abstract]   [Full Text] [Related]  

  • 3. EBV-positive high-grade B-cell lymphoma with MYC and BCL6 rearrangements.
    Craig A; Wen KW
    Blood; 2022 Jul; 140(4):406. PubMed ID: 35900784
    [No Abstract]   [Full Text] [Related]  

  • 4. Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study).
    Hilton LK; Collinge B; Ben-Neriah S; Alduaij W; Shaalan H; Weng AP; Cruz M; Slack GW; Farinha P; Miyata-Takata T; Boyle M; Meissner B; Cook JR; Ondrejka SL; Ott G; Rosenwald A; Campo E; Amador C; Greiner TC; Raess PW; Song JY; Inghirami G; Jaffe ES; Weisenburger DD; Chan WC; Beiske K; Fu K; Delabie J; Pittaluga S; Iqbal J; Wright G; Sehn LH; Savage KJ; Mungall AJ; Feldman AL; Staudt LM; Steidl C; Rimsza LM; Morin RD; Scott DW
    Blood; 2024 Aug; 144(5):525-540. PubMed ID: 38701426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
    Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EBV-positive low-grade follicular lymphoma transforming to EBV-negative high-grade B-cell lymphoma with MYC and BCL2 rearrangements.
    Nam MH; Hsieh YY; Chen BJ
    Pathology; 2022 Aug; 54(5):634-636. PubMed ID: 34872752
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
    Miyaoka M; Kikuti YY; Carreras J; Ikoma H; Hiraiwa S; Ichiki A; Kojima M; Ando K; Yokose T; Sakai R; Hoshikawa M; Tomita N; Miura I; Takata K; Yoshino T; Takizawa J; Bea S; Campo E; Nakamura N
    Mod Pathol; 2018 Feb; 31(2):313-326. PubMed ID: 28984304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous Regression of High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements: Case Report and Literature Review.
    Stanoszek LM; Smith LB; Grajewski K; Reneau JC; Wilcox R; Perry AM
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e120-e125. PubMed ID: 33060050
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
    Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
    Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 11. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inferior survival in high-grade B-cell lymphoma with
    McPhail ED; Maurer MJ; Macon WR; Feldman AL; Kurtin PJ; Ketterling RP; Vaidya R; Cerhan JR; Ansell SM; Porrata LF; Nowakowski GS; Witzig TE; Habermann TM
    Haematologica; 2018 Nov; 103(11):1899-1907. PubMed ID: 29903764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
    Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
    Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas.
    Behdad A; Bailey NG
    Surg Pathol Clin; 2016 Mar; 9(1):41-54. PubMed ID: 26940267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
    J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple hit B-cell lymphoma with diffuse kidney involvement sparing the glomeruli.
    Ali ND; Bains A
    Blood; 2019 Sep; 134(10):842. PubMed ID: 31488459
    [No Abstract]   [Full Text] [Related]  

  • 17. Detailed molecular analysis and evaluation of prognosis in cases with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
    Stengel A; Kern W; Meggendorfer M; Haferlach T; Haferlach C
    Br J Haematol; 2019 Jun; 185(5):951-954. PubMed ID: 30460680
    [No Abstract]   [Full Text] [Related]  

  • 18. Genomic profile of TdT
    Hamdan H; Luu L; Opsahl M; Weinberg O; Fuda F; Koduru P; Wilson K; Gagan J; Ramakrishnan Geethakumari P; Collins R; Chen W
    Cytometry B Clin Cytom; 2022 Nov; 102(6):448-450. PubMed ID: 36102633
    [No Abstract]   [Full Text] [Related]  

  • 19. Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes.
    Lue JK; Luttwak E; Rivas-Delgado A; Irawan H; Boardman A; Caron PC; David K; Epstein-Peterson Z; Falchi L; Ghione P; Hamlin P; Horwitz SM; Intlekofer AM; Johnson W; Kumar A; Moskowitz A; Noy A; Palomba ML; Steiner R; Stuver R; Torka P; Vardhana S; Zelenetz AD; Schoder H; Imber B; Yahalom J; Zhang Y; Galera P; Dogan A; Aypar U; Salles G
    Blood Cancer J; 2024 Oct; 14(1):178. PubMed ID: 39402034
    [No Abstract]   [Full Text] [Related]  

  • 20. High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma.
    Moore AM; Moshkin O; Swain GJ; Crocker S; LeBrun DP
    Diagn Pathol; 2018 May; 13(1):34. PubMed ID: 29793519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.